ID   MCIR1
AC   CVCL_A0DE
SY   Mayo Clinic Ibrutinib-Resistant Line 1
DR   Wikidata; Q108820864
RX   PubMed=34214199;
CC   Characteristics: Obtained from a ibrutinib-resistant tumor clone.
CC   Doubling time: 32 hours (PubMed=34214199).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=34214199).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=34214199).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 19-12-24; Version: 5
//
RX   PubMed=34214199; DOI=10.1111/ejh.13682; PMCID=PMC8654320;
RA   Wu X.-S., Nowakowski K.E., Abeykoon J.P., Manske M.K., Stenson M.J.,
RA   Timm M.M., Hanson C.A., Van Dyke D.L., Dasari S., Witzig T.E.;
RT   "MCIR1: a patient-derived mantle cell lymphoma line for discovering
RT   new treatments for ibrutinib resistance.";
RL   Eur. J. Haematol. 107:458-465(2021).
//